The mutation was found to be associated with BC [OR = 1.86, 95% CI = 1.26–2.75, p = 0.0018], especially among triple-negative BC cases with positive estrogen and progesterone receptors and negative for HER2 (OR = 3.56, 95% CI = 1.81–6.98, p = 0.0002). This evidence concerns the gene ERBB2 and breast cancer.